


# Croda Health Care



# Our purpose

## Smart science

- A strong history of combining **knowledge, passion** and **entrepreneurial spirit** to create, make and sell speciality ingredients that are relied upon by industries and consumers everywhere.
- **Sustainability** drives innovation, creating market-leading products while ensuring that we have a **positive impact** on the environment and society.


## to improve lives

- Ambition is to become the most sustainable supplier of innovative ingredients.
- By 2030 we will be Climate, Land and People Positive.

# Global supply chain


## Our global network at your service

37 Countries   85 Operating Sites   5,684 Employees




- **Global organisation** is the core to Croda
- **Multi-region R&D** provides us with diverse perspectives
- Due to multiple manufacturing sites, local stock and service, we ensure **secure supply**

# Broadening our pharma offering



- At the **smart end of the market**, delivering niche applications to our diverse customer base
- Becoming the **go to supplier** of excipients, adjuvants and lipid technologies
- Our **strategic move into vaccines and lipid technologies** has allowed us to work on many COVID-19 projects and ground-breaking developments using cutting edge adjuvant technologies
- **Avanti acquisition** has given us technology for pharma segments and pharma business services (catalogue sales, CMO, analytical services) and influence

# Health Care specialities around the globe



- A global network of dedicated Health Care specialists
- Increased manufacturing footprint in Japan, US and UK
- Doubled capacity for speciality excipients across three regions
- Invested £105 million in capacity expansions across our Health Care sites just within one year



Health Care manufacturing site



Health Care R&T innovation centre



Sales office

# Platforms for growth




## High Purity Excipients for Rx

- Super Refined™ excipient range highly valued by customers
- Continued innovation with unique solutions and purification technologies
- Substantial regulatory know-how and influence



## Vaccine Adjuvants

- Established adjuvant portfolio and expertise
- Industry-leading site quality credentials
- Strong pipeline of next generation vaccine adjuvants



## Lipid Technology

- Highest purity lipid reagents for research and pharmaceutical product development
- Custom synthesis and formulation
- Analytical and formulation services



# Speciality excipients

- Our speciality excipients have been stripped of impurities, residues and catalysts that could affect your API in a negative way
- This is responsible for our products' **superior performance**
  - Enhancing drug stability
  - Boosting shelf life
  - Improving product safety
  - Reducing patient irritation
  - Improving active efficacy



# Human vaccine adjuvant business

- Industry experience as a world-leading adjuvant specialist for vaccines serving the major human and veterinary vaccine producers globally
- More than 80 years of expertise
- GMP-certified and globally unique aseptic manufacturing facility
- Industry-leading R&T capabilities, resulting in a strong pipeline of innovative, efficacious vaccine adjuvants





# Lipid technology

## More than lipids

Solutions for the entire product cycle: research to commercialisation

- Research products: highest purity lipid reagents
- cGMP manufacturing: API and Contract Manufacturing
- Adjuvants: vaccine development
- Analytical services: lipid analysis
- Lipidomics: MS standards, antibodies and lipid toolbox
- Formulations: liposome and nanoparticles
- Equipment: liposome production tools
- Custom synthesis: synthesis and beyond



# Combating challenging infectious diseases and pathogens

- “Easy” vaccines have already been developed
- New, innovative vaccine adjuvants are required
- Alongside our partners, we develop adjuvants to target new diseases and pathogens: malaria, tuberculosis, HIV, staphylococcus aureus, shingles



## People Positive

- We will contribute to the successful development and commercialisation of **25%** of WHO listed pipeline vaccines
- By the end of 2024 our technology will be part of at least **10 clinical phase III** trials across at least 25% of the WHO-listed pipeline vaccines



# Latest recognitions in innovation and sustainability


- Avanti Polar Lipids received Sustainability Leadership Award by the American Chemistry Council (ACC) recognising the 'societal contribution' to the development and deployment of the Pfizer-BioNTech COVID-19 vaccine, June 2021
- Ranked first in Barron's Most Sustainable International Company listing April 2021
- Voted Most Admired Company in the British Chemical Sector for the Fourth Year Running
- Received EcoVadis Platinum status



# Our performance spectrum in Health Care



**Customer engagement**



**Formulation excellence & continuous improvement**



**Regulatory expertise**



**High quality & purity standards**

# Customer engagement

## Our aim is helping you find YOUR solution

- Listening and understanding customer and market needs
- Being open, approachable & flexible
- Facilitating access to our dedicated experts
- Enhanced customer experience and value by offering digital solutions



# Formulation excellence and continuous innovation

## Meeting your formulation needs

- Dedicated and experienced team always working to maximise formulation performance
- Expertise based on long-term experience
- Development centres around the globe

## ... and being partners in innovation

- Excellent network, including over 500 universities and partners
- Continuous research to provide data to support our claims
- Research into novel methodologies and technologies



# Regulatory expertise



**Jette Kjeldal**, *Quality and Regulatory Director - Vaccine Adjuvants*  
Expert in Development, Production and Quality Assurance under GMP

**Dr. Miquel Mir**, *Global Quality and Regulatory Manager Pharma Excipients*  
Expert in pharma excipients, IPEC and EXCiPACT



**Lonna Tucker**, *Executive Director of Regulatory Affairs and Compliance*  
Expert in regulatory filings at all phases of development, including commercialization

**Dr. Richard Cawthorne**, *Research & Technology Fellow*  
Expert in monograph and USP Excipients Expert Committee Member





# High quality and purity standards

- We offer excipients of high purity and world-leading vaccine adjuvants to satisfy quality requirements
- Our Super Refined™ excipients provide proven benefits in comparison with standard grades
- Our excipients and adjuvants are designed to maximise performance and minimise risk



# Our goal

Helping you succeed by providing:

- Quality
- Innovation and
- Expertise

to maximise the performance of your active pharmaceutical ingredients.



# Thank you !

- Visit our website at <https://www.crodahealthcare.com/>
- Follow us on LinkedIn



08/21 HTCMP183v2 EN

**Non-warranty**

The information in this publication is believed to be accurate and is given in good faith, but no representation or warranty as to its completeness or accuracy is made. Suggestions for uses or applications are only opinions. Users are responsible for determining the suitability of these products for their own particular purpose. No representation or warranty, expressed or implied, is made with respect to information or products including, without limitation, warranties of merchantability, fitness for a particular purpose, non-infringement of any third-party patent or other intellectual property rights including, without limit, copyright, trademark and designs. Any trademarks identified herein are trademarks of the Croda group of companies.  
©2021 Croda Singapore

**CRODA**